Get the Stockscreener App
0.00
100.00%
-14.00
Ventyx Biosciences Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
See More
Previous Close:
$14.00
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$1.00B
Revenue:
-
Net Income/Loss:
$-106.61M
P/E Ratio:
0.00
EPS:
-1.4995
Net Cash Flow:
$-87.87M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$25.00
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Name
Ventyx Biosciences Inc
Sector
Industry
Phone
(760) 407-6511
Address
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Compare VTYX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
0.00 | 1.00B | 0 | -106.61M | -87.87M | -1.4995 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-12-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Mar-12-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-07-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-07-23 | Downgrade | Stifel | Buy → Hold |
| Nov-07-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Wells Fargo | Overweight |
| Dec-19-22 | Initiated | Goldman | Buy |
| Nov-17-22 | Initiated | Morgan Stanley | Overweight |
| Sep-07-22 | Initiated | Stifel | Buy |
| Sep-01-22 | Initiated | H.C. Wainwright | Buy |
| May-09-22 | Initiated | Credit Suisse | Outperform |
| Mar-31-22 | Initiated | Canaccord Genuity | Buy |
| Feb-01-22 | Initiated | Oppenheimer | Outperform |
| Nov-15-21 | Initiated | Jefferies | Buy |
| Nov-15-21 | Initiated | Piper Sandler | Overweight |
View All
Ventyx Biosciences Inc Stock (VTYX) Latest News
Ventyx Biosciences stock (US92276F1003): clinical setbacks keep investors on edge - AD HOC NEWS
Affinity Asset Advisors amends 13G/A for Ventyx Bioscience (VTYX) — 0 shares reported - Stock Titan
Ventyx Biosciences stock (US92276F1003): Acquired by Eli Lilly for $1.2B in January - AD HOC NEWS
In the mix post-Ventyx, more NLRP3s to seize? - BioWorld News
Ventyx Biosciences, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
LifeSci Capital downgrades Ventyx Biosciences (VTYX) - MSN
Eli Lilly to acquire Ventyx Biosciences in $1.2 billion deal - MSN
Eli Lilly nears deal for Ventyx Biosciences at $14/shareWSJ - msn.com
Oppenheimer Maintains Ventyx Biosciences (VTYX) Outperform Recommendation - MSN
Ventyx Biosciences stock (US92276F1003): Is its immunology pipeline strong enough to unlock biotech - AD HOC NEWS
Winners Losers: Does Ventyx Biosciences Inc have a sustainable dividend2026 Weekly Recap & Real-Time Market Sentiment Reports - baoquankhu1.vn
Can Ventyx Biosciences Inc benefit from deglobalization2026 Trade Ideas & Step-by-Step Swing Trade Plans - baoquankhu1.vn
VTYX Stock: A Deep Dive into Ventyx Biosciences - Bitget
Insider Sell: How does Ventyx Biosciences Inc correlate with Nasdaq2026 Growth vs Value & Trade Opportunity Analysis - baoquankhu1.vn
Levels Update: What are Ventyx Biosciences Incs earnings expectations2026 Highlights & Low Risk High Reward Ideas - baoquankhu1.vn
Growth Recap: Will Ventyx Biosciences Inc stock hit new highs in YEARProduct Launch & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Can Ventyx Biosciences Inc outperform in the next rally2026 Fundamental Recap & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Ventyx Biosciences completes $1.2 billion acquisition by Eli Lilly, delists from Nasdaq - Investing.com
Ventyx Biosciences stock: Acquired for $14—What it means for you now - AD HOC NEWS
VTYX SEC FilingsVentyx Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Oppenheimer downgrades Ventyx Biosciences (VTYX) - MSN
Will Ventyx Biosciences Inc stock hit new highs in YEAR2026 Stock Rankings & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Aug Decliners: Is Ventyx Biosciences Inc forming a double bottomStop Loss & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Published on: 2026-03-27 07:56:14 - baoquankhu1.vn
Ventyx Biosciences stock faces uncertainty after pipeline setback and strategic review - AD HOC NEWS
If You Invested $1,000 in Ventyx Biosciences, Inc. (VTYX) - Stock Titan
Market Fear: How does Ventyx Biosciences Inc score in quality rankings2026 Trading Recap & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Aug PostEarnings: Can Ventyx Biosciences Inc benefit from deglobalizationEarnings Trend Report & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Aug Swings: Is Ventyx Biosciences Inc stock forming a triangle pattern2026 Stock Rankings & Capital Efficient Trading Techniques - baoquankhu1.vn
[15-12G] Ventyx Biosciences, Inc. SEC Filing - Stock Titan
Growth Recap: Does Ventyx Biosciences Inc stock reflect fundamentalsWeekly Trade Review & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Breakout Move: Is Ventyx Biosciences Inc stock overvalued or fairly priced2026 Update & Consistent Profit Trading Strategies - baoquankhu1.vn
[EFFECT] Ventyx Biosciences, Inc. SEC Filing - Stock Titan
Ventyx Biosciences Stock: Retail Buzz Spikes After Phase 2 Win In Obesity And Heart Risk Study - MSN
Ventyx Biosciences (NASDAQ:VTYX) Upgraded to Hold at Wall Street Zen - MarketBeat
Why Ventyx Biosciences Inc. stock is rated strong buyJuly 2025 Weekly Recap & High Return Trade Guides - Naître et grandir
Lilly nearing $1 billion deal with biotech Ventyx, WSJ says - MSN
Assessing Ventyx Biosciences (VTYX) Valuation After A Sharp 90 Day Share Price Rebound - simplywall.st
Eli Lilly buys Ventyx (VTYX) in all-cash $14 per share merger - Stock Titan
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Ventyx Biosciences (VTYX) exec records option dispositions in $14 Lilly buyout - Stock Titan
Ventyx Biosciences (VTYX) cashed out at $14 per share in Eli Lilly merger - Stock Titan
COO’s Ventyx (VTYX) options cashed out as Eli Lilly merger closes - Stock Titan
Lilly–Ventyx (VTYX) merger cancels director stock options at $14 - Stock Titan
Ventyx Biosciences (VTYX) director’s options cancelled in Eli Lilly cash merger - Stock Titan
Ventyx (VTYX) director’s options and shares cashed out at $14 in Eli Lilly merger - Stock Titan
Eli Lilly deal converts Ventyx (VTYX) CMO’s shares and options to cash - Stock Titan
Eli Lilly and Company completed the acquisition of Ventyx Biosciences, Inc. from New Science Ventures, LLC, Affinity Asset Advisors, LLC, The Vanguard Group, Inc., and others. - marketscreener.com
Ventyx Biosciences (VTYX) deregisters registered resale shares after merger - Stock Titan
Ventyx Biosciences (NASDAQ: VTYX) deregisters shares after Eli Lilly merger - Stock Titan
Ventyx Biosciences Completes Cash Merger and Equity Payout - TipRanks
Ventyx Biosciences Inc Stock (VTYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):